Wed, Jul 23, 2014, 4:22 AM EDT - U.S. Markets open in 5 hrs 8 mins

Recent

% | $
Click the to save as a favorite.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • censored50 censored50 Jun 4, 2013 9:48 AM Flag

    From Motley Fool...

     

    Back on May 19, I wrote an article on Aegerion called “Too Many Questions Make This Thursday Mover A Sell.” Basically, the article walks the reader through all of the speculation that has created its large movement; including the company’s misleading statements regarding Juxtapid’s potential.

    Juxtapid will be used to treat homozygous familial hypercholesterolemia. However, “rare cholesterol disease” is much easier when discussing the disease. My first article showed how the patient population for this disease is very scattered, as the company indicates it to be one size (3,000 total domestically) while the FDA estimates it to be significantly smaller (just 315 annual claims).

    My conclusion from the previous article is that the true number of “rare cholesterol disease” is somewhere in the middle. When considering that there is already a drug on the market, Sanofi’s Kynamro, to treat the exact same condition I predicted peak sales to be $250 million for Juxtapid – which I believe is vital to assessing and valuing the company.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
27.68+0.27(+0.99%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.